Temporal effects of Sprouty on lung morphogenesis  by Perl, Anne-Karina T et al.
Temporal effects of Sprouty on lung morphogenesis
Anne-Karina T. Perl,a Isamu Hokuto,a Maria-Antonietta Impagnatiello,b Gerhard Christofori,c
and Jeffrey A. Whitsetta,*
a Division of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229-3039, USA
b Boehringer Ingelheim Austria, Dr. Boehringer Gasse 5-11, 1121 Wien, Austria
c Institute of Biochemistry and Genetics, University of Basel, Vesalgasse 1, CH-4051 Basel, Switzerland
Received for publication 8 November 2002, revised 17 January 2003, accepted 27 January 2003
Abstract
Paracrine signaling mediated by FGF-10 and the FGF-R2IIIb receptor is required for formation of the lung. To determine the temporal
requirements for FGF signaling during pulmonary morphogenesis, Sprouty-4 (Spry-4), an intracellular FGF receptor antagonist, was
expressed in epithelial cells of the fetal lung under control of a doxycycline-inducible system. Severe defects in lobulation and severe lung
hypoplasia were observed when Spry-4 was expressed throughout fetal lung development (E6.5–E18.5) or from E6.5 until E13.5. Effects
of Spry-4 on branching were substantially reversed by removal of doxycycline from the dam at E12.5, but not at E13.5. In contrast, when
initiated late in development (E12.5 to birth), Spry-4 caused less severe pulmonary hypoplasia. Expression of Spry-4 from E16.5 to E18.5
reduced lung growth and resulted in perinatal death due to respiratory failure. Expression of Spry-4 during the saccular and alveolar stages,
from E18.5 to postnatal day 21, caused mild emphysema. These findings demonstrate that the embryonic-pseudoglandular stage is a critical
time period during which Spry-sensitive pathways are required for branching morphogenesis, lobulation, and formation of the peripheral
lung parenchyma.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Formation of the murine lung is initiated on E9.0–E9.5
by evagination of tissue from the lateral, esophageal–tra-
cheal sulcus from the foregut endoderm. Respiratory tu-
bules elongate and branch as the epithelial cells proliferate
within the splanchnopleural mesenchyme. Stereotypic
branching of the respiratory tubules is achieved by precise
temporal and spatial signals that control cell shape, prolif-
eration, differentiation, and/or migration to form the con-
ducting airways (trachea, bronchi, and bronchioles) and
peripheral lung parenchyma, including the alveoli. Forma-
tion of the pulmonary vasculature, including pulmonary
arteries, capillaries, and veins, accompanies the respiratory
tubules, ultimately providing a rich vascular supply to the
alveolar regions to accommodate gas exchange after birth.
While the mechanisms underlying the orderly process of
branching morphogenesis of the lung are as yet poorly
defined, increasing evidence supports the critical role of
signaling by fibroblast growth factor receptors, their li-
gands, and antagonists in the process. Inhibition of FGF
receptor signaling in the developing respiratory epithelium
with a dominant-negative FGF receptor or a truncated
FGF-R2 isoform of the FGF receptor caused pulmonary
hypoplasia in transgenic mice in vivo (Celli et al., 1998;
Peters et al., 1994). Similarly, targeted deletion of FGF-10
caused complete pulmonary agenesis (Min et al., 1998).
Selective proliferation and migration of subsets of respira-
tory epithelial cells are required to accomplish the precise
pattern of branching characteristic of the mammalian lung.
Drosophila Spry (Dspry) is an antagonist of FGFR sig-
naling during tracheal morphogenesis (Hacohen et al., 1998;
Placzek and Skaer, 1999). During formation of the Dro-
sophila trachea, DSpry prevents neighboring cells from
elaborate branching, functioning in a non-cell-autonomous
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manner (Hacohen et al., 1998). More recent data support the
concept that DSpry is an intracellular inhibitor of FGF
signaling, and that its membrane localization is essential for
function (Casci et al., 1999; Impagnatiello et al., 2001).
During Drosophila eye development and oogenesis, DSpry
also inhibited FGFR signaling in a cell-autonomous manner
controlling the number of neurons and glia cells (Casci et
al., 1999; Kramer et al., 1999; Reich et al., 1999). Since
DSpry interferes with signaling from various receptor-ty-
rosine kinases (RTK), such as Torso and Sevenless, DSpry
may function as a general inhibitor of RTK signal transduc-
tion (Casci et al., 1999; Reich et al., 1999). DSpry associates
with various intracellular components of the FGFR signal-
ing cascade, namely Gap1 and Drk, the Drosophila homo-
logue of Grb2 (Casci et al., 1999). During eye development,
DSpry inhibits p42/44 mitogen-activating protein (MAP)
kinase activation at the level of Ras (Casci et al., 1999),
whereas during wing development, it may interfere down-
stream of RAF (Reich et al., 1999).
Three human, four murine, and two avian genes encod-
ing homologues of Drosophila Spry were identified (Cham-
bers and Mason, 2000; de Maximy et al., 1999; Hacohen et
al., 1998; Minowada et al., 1999; Tefft et al., 1999).
Mspry-1 and Mspry-2 inhibited FGF- and VEGF-induced
endothelial cell proliferation and differentiation, by repress-
ing pathways leading to p42/44 MAP kinase activation
(Impagnatiello et al., 2001). During zebrafish development,
Spry-4 expression is colocalized and dependent on FGF-8
and FGF-3 signaling. Sprouty antagonizes by interfering
with FGF signaling downstream of FGFR1, downregulating
MAP kinase activity. Loss of Spry expression resulted in
overexpression of FGFs (Fu¨rthauser et al., 2002). Blocking
the FGF pathway in early Xenopus embryos inhibits meso-
derm induction and results in truncation of the anterior–
posterior axis (Nutt et al., 2001).
Expression of murine Spry-2 and -4 resulted in the
repression of FGF-mediated limb development in chicken
(Minowada et al., 1999), whereas ablation of Spry-2
expression in the cultured embryonic mouse lungs led to
an increase in branching of respiratory tubules, a process
induced by FGFs (Tefft et al., 1999). Constitutive ex-
pression of murine Spry-2 in the developing mouse lung
using the SP-C promoter reduced branching and inhibited
epithelial proliferation (Mailleux et al., 2001). As ob-
served with DSpry, expression of murine and avian Spry
was stimulated by FGF activity, providing feedback reg-
ulation of the signal transduction pathway (Chambers and
Mason, 2000; Hacohen et al., 1998; Mailleux et al., 2001;
Minowada et al., 1999).
While FGF-10 and FGF-R2IIIb are critical for formation
of the lung, it is presently unclear whether FGF signaling is
continuously required for proliferation of pulmonary epithe-
Fig. 1. Constructs used for conditional expression of Spry-4. (A) The murine Spry-4 cDNA was inserted into (tetO)7CMV-bGH-polyA vector, and the
resulting transgenic mice were bred to SP-C-rtTA transgenic mice to produce double transgenic mice. After doxycycline, double transgenic progeny express
Spry-4 mRNA. (B) Transgene-specific murine Spry-4 and -actin mRNAs were assessed by RT-PCR in adult mouse lung after 48 h of doxycycline () and
compared with untreated animals (). M, marker; SP-C-rtTA/(tetO)7Spry-4, double transgenic mice; (tetO)7Spry-4, single transgenic; wt, wild type mice;
T, Tail DNA () on doxycycline; () off doxycycline. (Left panels) Spry-4; RT, cDNA reaction with reverse transcriptase, RT, cDNA reaction without
reverse transcriptase; (right panels) for -actin. Double transgenic mice expressed the transgene at high levels following doxycycline. Low levels of Spry-4
mRNA detected in the absence of doxycycline had no observable biological effect.
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lial cells forming the lung or whether FGFs influence com-
mitment or survival of critical subsets of lung progenitor
cells at precise times during its morphogenesis. In the
present work, we demonstrate that Spry’s antagonistic ac-
tion on FGF-mediated lung formation is temporally re-
stricted. Spry-4 inhibited branching morphogenesis prior to
E13 without altering cell differentiation. Expression of
Spry-4 during the late perinatal and postnatal period caused
emphysema. The results indicate that Spry-4-sensitive path-
ways are required for commitment or expansion of a critical
subset of lung progenitor at precise stages of lung develop-
ment.
Fig. 2. Lung morphology at E16.5 after continuous expression of Spry-4. Morphology of wildtype (A, C, E) and double transgenic SP-C-rtTA/(tetO)7Spry-4
(B, D, F) embryos are shown at E16.5. The dams were treated with doxycycline from E6.5 to E16.5 (A, B) Whole thorax; (C, D) lung and heart; (E, F) higher
magnification of left lung lobe. E, esophagus; H, heart; T, trachea. In the double transgenic mouse, the chest cavity is of normal size and shape but nearly
empty, reflecting severe lung hypoplasia (B), reduction in primary and secondary branching resulted in three lobes (D), and loss of lung periphery (D, F).
Airways are blood-filled, outlining the bronchial tree (D, F). Size bars equal 2 mm in (A–D), 0.5 mm in (E, F).
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Materials and methods
Transgenic constructs
To antagonize FGFR signaling during lung morpho-
genesis, transgenic mice bearing a construct consisting of
the rtTA binding element (tetO)7 linked to an inactive
CMV minimal promoter driving expression of murine
Spry-4, (tetO)7Spry-4, were generated and mated to
transgenic SP-C-rtTA mice. SP-C-rtTA mice are trans-
genic mice expressing the rtTA activator under the con-
trol of the human surfactant protein C (SP-C) promoter
and have been described previously (Tichelaar et al.,
1999; Perl et al., 2002a). Transgenic (tetO)7Spry-4 mice
were generated by oocyte injection of a construct in
which the mouse Spry-4 cDNA was inserted between the
(tetO)7CMV promoter and the 3 untranslated region of
the bovine growth hormone gene. Founders were identi-
fied by PCR analysis and confirmed by Southern blot
analysis. Single transgenic (tetO)7Spry-4 or SP-C-rtTA
mice were without abnormalities and were maintained in
microisolator cages. Double transgenic mice were gener-
ated by crossing SP-C-rtTA activator and (tetO)7Spry-4
operator mice. Founder lines were screened for utility
based on the phenotype of hypoplastic lungs after tetra-
cycline induced transgene activation. Lung hypoplasia
was observed in two distinct Spry-4-expressing founder
lines. Line 9.1 was chosen for further investigations.
Genotyping
Transgenic mice were identified by using PCR primers
specific for each transgene (5 SP-C promoter: 5-GAC
ACA TAT AAG ACC CTG GTCA-3 and the 3 primer in
rtTA coding sequence (5-AAA ATC TTG CCA GCT TTC
CCC-3), (5 tetO promoter: 5-CAC CGG GAC CGA TCC
AGC-3) and the 3 Spry-4 primer (5-GAA GTG CTG
CTA CTG CTG CTT ACAG-3). Amplification of PCR
products was performed as following: denaturation at 94°C
for 5 min, 30 cycles of denaturation at 94°C for 30 s,
annealing at 58°C (SP-C-rtTA), or 60°C (tetO-Spry-4) for
30 s, and extension at 72°C for 30 s followed by a 5-min
extension at 72°C.
Animal use and doxycycline administration
Animals were housed in pathogen-free conditions in ac-
cordance with institutional guidelines. Animals were mated
and gestation dated by detection of the vaginal plug and
correlated with length and weight of each pup at the time of
sacrifice. Dams bearing double transgenic pups were main-
tained on doxycycline in the food (25 mg/g; Harlan Teklad,
Madison, WI) or drinking water with doxycycline (Sigma
Chemical Co., St. Louis, MO) at 1 mg/ml for various time-
spans. The mice were killed by either placing them in a CO2
chamber or by injecting them with 0.2–0.3 cc anesthetic
containing ketamine, xylazine, and acepromazine. All ex-
periments were done with at least three pregnant females,
resulting in at least five double transgenic mice per time
point and per assay and compared with single and double
transgenic littermates.
RT-PCR
Adult mice were placed on doxycycline for 48 h prior to
killing. Lung tissues were homogenized in Trizol reagent
(Life Technologies, Rockville, MD), and RNA was ex-
tracted according to the manufacturer’s instructions. RNA
was treated with DNase prior to cDNA synthesis. RNA (5
g) was reverse transcribed and analyzed by PCR for
Spry-4 mRNA. These primers were also used for genotyp-
ing. For normalization, PCR for -actin mRNA was per-
formed. To control for DNA contamination, PCRs for
Spry-4 and -actin were also conducted on samples in the
absence of reverse transcriptase in the cDNA reaction.
Lung histology and in situ hybridization
Mouse embryos were harvested according to their ges-
tational age. Animals were decapitated, and the thorax was
fixed overnight in 4% paraformaldehyde at 4°C. Lungs of
postnatal day 21 double transgenic mice and controls lungs
were inflation fixed overnight at 4°C by using 4% parafor-
maldehyde at 25 cm of pressure. All samples for histology
were washed with PBS, dehydrated through a graded series
of ethanol, and processed for paraffin embedding. Sections
(5 m) were loaded onto silianized slides. All stainings
were performed on at least three different animals for each
marker.
Fig. 3. Expression of TTF-1, CCSP, proSP-C, and Shh. Immunohistochemical analyses of the expression of TTF-1 (A, E), proSP-C (B, F), and CCSP (C,
G) and Shh (D, H) on E17.5–E18.5-old wild type (A–D), and SP-C-rtTA/(tetO)7Spry-4 (E–H) lung sections. The dam was treated with doxycycline from
E6.5 until killing. Note the presence of respiratory epithelium (TTF-1-positive), type II cells and precursors (proSP-C-positive), and nonciliated bronchiolar
cells (CCSP-positive) in the hypoplastic lungs. While peripheral epithelial cells were markedly decreased in number, morphology and immunostaining of the
remaining cells were appropriate for the saccular stage of development. Spatial distribution and levels of expression of Shh were maintained in the conducting
airways. Bar, 50 m.
Fig. 4. Spry-4 caused defects in branching morphogenesis at E12.5. Lungs of wild type (A–C) and double transgenic SP-C-rtTA/(tetO)7Spry-4 (D–F)
littermates at E12.5 (A, D), E13.5 (B, E), and E14.5 (C, F) are shown. The dams were treated with doxycycline from E6.5 to day of sacrifice. Five lobes
were observed in the wild type mice, while three lobes were observed in mutant animals. Lungs are shown at the same magnification. 1, cranial; 2, medial;
3, caudial; 4, accessory; 5, left lobe; T, trachea. Bar, 2 mm.
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In situ hybridization was performed with 35S-nucleotide
labeled riboprobes to assess the sites of expression of FGF-
10, FGF-18, Spry-2, and Spry-4 mRNAs using sense and
antisense probes from full-length mouse cDNA clones.
Sense and antisense riboprobes were generated from
pGEM-T (Promega, Madison, WI) containing the full-
length FGF-10, FGF-18, Spry-2, or Spry-4 cDNAs that
were transcribed in vitro with a Riboprobe transcription kit
(Promega, Madison, WI). Conditions and solutions for hy-
bridization are essentially as previously described (Wert et
al., 1993). Slides were dipped in Kodak NTB2 emulsion,
exposed for 1–4 weeks, and developed with Kodak D19
developer following manufacturer’s protocols.
Immunohistochemistry
Tissue sections were stained with hematoxylin–eosin,
orcein, and trichrome. Immunohistochemistry for thyroid
transcription factor 1 (TTF-1), proSP-C, CCSP, SHH, and
platelet endothelial cell adhesion molecule-1 (PECAM-1)
were performed as previously described (Tichelaar et al.,
2000; Whitsett et al., 2002). For BrdU incorporation, ani-
mals were injected intraperitoneally with bromodeoxyuri-
dine (BrdU; 1 mg/g body weight) and killed 2 h thereafter.
BrdU-labeled cells were detected by immunohistochemical
staining using mouse monoclonal antibody in accordance
with the manufacturer’s instructions (Zymed Laboratories,
Inc., San Francisco, CA).
Lung explant culture
Lungs were isolated from mouse embryos at embryonic
day E12.5 from SP-C-rtTA and (tetO)7Spry-4 crosses,
yielding 25% double transgenic progeny. Lungs were cul-
tured on a 13-mm diameter and 0.8-m pore size Track-
Etch membrane floating in 1 ml of Dulbecco’s Modified
Eagle’s Medium (DMEM). Lungs were cultured in the
presence and absence of doxycycline (10 g/ml; Sigma, St.
Louis, MO). Human recombinant FGF-7 (Prepro Tech. Inc.,
Rocky Hill, NJ) was diluted in PBS and added to each well
at final concentrations of 15 ng/ml. Lungs were cultured at
37°C in a 5% humidified 95% CO2 air incubator. Photo-
graphs were taken at the same magnification with the use of
a Nikon SMZ-U stereoscope and a Nikon Cool PIX5000
digital camera. All photographs were processed in Adobe
Photoshop and Aldus Freehand.
Results
Spry-4, normally expressed in the lung mesenchyme,
was the most active FGF antagonist of various family mem-
bers tested (De Maximy et al., 1999; M.-A.I. and G.C.,
unpublished observations). Spry-4 was therefore expressed
in the respiratory epithelium of transgenic mice. Doxycy-
cline inducible (tetO)7Spry-4 transgenic mice were gener-
ated and crossed to transgenic mice in which the human
surfactant protein-C promoter controls synthesis of the re-
verse tetracycline transactivator (SP-C-rtTA) (Perl et al.,
2002a; Tichelaar et al., 2000) (Fig. 1A). Spry-4 mRNA was
readily detected in lungs of double transgenic SP-C-rtTA/
(tetO)7Spry4 mice when treated with doxycycline. Spry-4
mRNA was undetectable in the absence of the rtTA trans-
gene (Fig. 1B), and was barely detectable in double trans-
genic mice in the absence of doxycycline. Treatment of the
dam with doxycycline induced expression of transgenes in
lungs of double transgenic mice within 16 h, and transgene
expression ceases approximately 24–48 h after removal of
the drug (Perl et al., 2002a; Tichelaar et al., 2000).
Continuous expression of Spry-4 caused severe lung
hypoplasia
The (tetO)7Spry-4 transgene was transmitted in ratios
predicted by Mendelian inheritance. When the dam was
maintained on doxycycline from E6.5–E16.5, a marked
reduction in pulmonary parenchyma was noted in all dou-
ble, but single transgenic mice or wild type littermates (Fig.
2). Hypoplastic lungs were found in otherwise normal chest
cavities (Fig. 2B). Spry-4 markedly inhibited branching
morphogenesis, generally resulting in lungs with three, in-
stead of five lobes (Fig. 2D). While trachea and lobar
bronchi were present, the mass of peripheral lung paren-
chyma was markedly reduced (Fig. 2F). Thus, expression of
Spry-4 throughout lung development caused severe pulmo-
nary hypoplasia (Fig. 2B, D, and F). Decreased lobulation
caused by Spry-4 was observed as early as E12.5 (see Fig.
4D).
Spry-4 does not alter epithelial cell differentiation
Electronmicroscopic analyses of the respiratory epithe-
lium on E16.5 demonstrated stage appropriate differentia-
tion of type II cells and Clara cells in both conducting and
Fig. 5. Mitotic index by BrdU staining. Lung histology and BrdU incorporation were assessed in wild type (A–C) and double transgenic SP-C-rtTA/
(tetO)7Spry-4 (D–F) littermates maintained on doxycycline from E6.5 until killing at E12.5 (A, D), at E13.5 (B, E), and at E14.5 (C, F). Mitotic index was
determined by BrdU immunohistochemistry and described as percentage of total cells. At all time points, the percentage of mitotic cells and the epithelial
mesenchymal ratio was unchanged. Bar, 50 m.
Fig. 6. Effects of Spry-4 during lung bud culture. Lungs of E12.5 controls and double transgenic SP-C-rtTA/(tetO)7Spry-4 embryos were cultured for 60 h
in the presence and absence of doxycycline. Branching was not inhibited in controls in the presence of doxycycline (A, D, G, J). Branching was not inhibited
in double transgenic lung explants in the absence of doxycycline (B, E, H, K). Culture of double transgenic lung explants in the presence of doxycycline
inhibited branching (C, F, I, L); note the continued elongation of the nonbranching tubules in the double transgenic lungs in the presence of doxycycline.
Size bar, 1 mm.
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peripheral airways (data not shown). Type II cells, with
nascent lamellar bodies and extensive microvillar surfaces,
were observed. Ciliated cells were readily apparent in the
conducting airways (data not shown). Immunohistochemi-
cal staining for differentiation markers selective for proxi-
mal and peripheral respiratory epithelial cells was assessed
in hypoplastic lungs from the double transgenic embryos
during the saccular stage of development (E17.5–E18.5).
The spatial pattern of expression of TTF-1 (Fig. 3A and E)
and proSP-C (Fig. 3B and F), both markers of distal respi-
ratory epithelial cells, was maintained. However, reduced
numbers of TTF-1 and proSP-C staining cells were ob-
served, consistent with a general decrease in the mass of
peripheral respiratory epithelial cells. Respiratory epithelial
cells in the peripheral airways stained for proSP-C, indicat-
ing maturation and differentiation of the alveolar type II
cells. Conducting airways from Spry-4-expressing mice
were lined by ciliated and nonciliated respiratory epithelial
cells, the latter staining for CCSP, a Clara cell differentia-
tion marker (Fig. 3C and G). Staining for CCSP was main-
tained in the conducting airways, indicating that cellular
differentiation continued despite the branching defect
caused by Spry-4. Immunohistochemistry for sonic hedge-
hog (Shh) also did not reveal any differences in its spatial
distribution or levels of expression (Fig. 3D and H). Thus,
the proximal–distal patterns of gene expression along the
developing airways were not disturbed by Spry-4.
Early lobulation defects and lung hypoplasia in Spry-4-
expressing mice
Lung morphogenesis was assessed in double transgenic
mice treated from E6.5 to E12.5, E6.5 to E13.5, and E6.5 to
E14.5 (Fig. 4). Mutant lungs had three instead of five lobes
(Fig. 4D–F). Cranial right lobe, medial right lobe, and left
lobe were present but smaller; the caudal right and acces-
sory lobes were absent. Histological analysis of the mutant
lungs on days E12.5, E13.5, and E14.5 demonstrated rela-
tively normal histology of trachea, and lobar bronchi in spite
of severe reductions in peripheral lung tissue. Decreased
numbers of peripheral bronchioles and loss of peripheral
lung buds were observed, although the organization of ep-
ithelial and mesenchymal structures was generally main-
tained (Fig. 5).
Effects of Spry-4 on cell proliferation
Mitotic indices were assessed by BrdU incorporation in
both mesenchyme and epithelial compartments of wild type
and Spry-4-expressing mice maintained on doxycycline
from E0 at E12.5, E13.5, and E14.5 (Fig. 5). BrdU-positive
and-negative cells in the epithelium and mesenchyme were
counted from complete cross-sections of lungs from five
Spry-4-expressing and wild type pups at each time point.
The labeling index, the percentage of positive cells from
total number of cells counted, was not changed at any age.
At E13.5 and E14.5, the epithelial–mesenchymal ratio of
labeled and unlabeled cells was not altered (Fig. 5). At
E12.5, the percentage of all epithelial cells was moderately
reduced; however, the difference was not statistically sig-
nificant (17.4  1.87% to 12.3  2.47%; P  0.132) by
ANOVA.
Spry-4 inhibits branching and FGF-7-induced cyst
formation in vitro
Lungs from E12.5 embryos derived from timed matings
of SP-C-rtTA and (tetO)7Spry-4 mice were cultured in the
presence and absence of doxycycline (Fig. 6). Branching of
the lungs from single transgenic or wildtype mice was not
altered by doxycycline. Lung branching was inhibited in
explants from double transgenic SP-C-rtTA/(tetO)7Spry-4
mice in the presence, but not in the absence of doxycycline.
However, elongation of lung tubes was not inhibited in
Fig. 7. Spry-4 inhibits effects of FGF-7 in vitro. Lungs of E12.5 controls
and double transgenic SP-C-rtTA/(tetO)7Spry-4 embryos were cultured for
60 h in the presence of 15 ng/ml FGF-7. Cystic lesions were observed in
the presence of doxycycline in control lung explants (A, D, G, J) and in
explants cultured from double transgenic mice in the absence of doxycy-
cline (B, E, H, K). FGF7-induced cyst formation was inhibited in lungs
from double transgenic mice in the presence of doxycycline (C, F, I, L).
Size bar, 1 mm.
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Spry4-expressing lung explants (Fig. 6C, F, I, and L), indi-
cating ongoing proliferation of the residual tubules. Lungs
from double transgenic E12.5 embryos were cultured in the
presence of 15 ng/ml FGF-7 (Fig. 7). After 36 and 60 h of
culture, dilated cysts were found in FGF-7-treated lung
explants from double transgenic SP-C-rtTA/(tetO)7Spry-4
mice and in control lungs but not in doxycycline-treated
lungs of double transgenic mice. Thus, Spry-4 blocked
branching morphogenesis and inhibited effects of FGF-7
effects in vitro.
Expression patterns of FGF7, FGF-10, FGF-18, Spry-2,
and Spry-4 mRNA
FGF-10, FGF-18, Spry-2, and Spry-4 mRNAs were as-
sessed in E13.5 wild type and doxycycline-treated double
transgenic SP-C-rtTA/(tetO)7Spry-4 lungs by in situ hybrid-
ization analyses (Fig. 8). FGF-10 mRNA was detected in
the mesenchyme at the tips of epithelial buds in the control
mice (Fig. 8A). Epithelial expression of Spry-4 increased
FGF-10 mRNA in the mesenchyme at the tips of the lung
tubules and along the tubes (Fig. 8B). Distribution of
FGF-18 mRNA was unaltered by Spry-4 expression, but the
intensity of the signal was slightly increased (Fig. 8C and
D). Expression of FGF7, BMP4, and FGFR2IIIb mRNAs
was unchanged (data not shown). Spry-2 mRNA (Fig. 8E
and F) was detected in the epithelial cells at the tips of the
lung tubes in wild type and affected lungs at comparable
levels. Endogenous Spry-4 mRNA was detected diffusely
throughout the mesenchyme at low levels in wild type and
mutant lungs (Fig. 8G and H). Transgenic Spry-4 mRNA
was expressed at high levels in most of the respiratory
epithelial cells in doxycycline-treated double transgenic SP-
C-rtTA/(tetO)7Spry-4 lungs (Fig. 8H). In situ hybridization
with sense probes revealed no specific hybridization (data
not shown).
Reversibility of lung lobulation at E12.5
While continuous expression of Spry-4 caused severe
lung hypoplasia, it is unclear whether effects of Spry-4 were
related to inhibition of branching and proliferation through-
out lung morphogenesis or to the failure of expansion of
progenitor cells that normally form the peripheral lung pa-
renchyma. In order to address whether Spry-4 affects lung
morphogenesis throughout development or its actions were
restricted in time, dams were treated with doxycycline be-
fore E13.5 or after E12.5, and lungs were compared at the
end of embryonic development at E18.5 (Fig. 9). Lungs of
untreated double transgenic mice were of normal size and
comparable to single transgenic and wildtype littermates
(Fig. 9A). After continuous doxycycline treatment from
E0.5 to E18.5, lungs of double transgenic mice were mark-
edly hypoplastic and consisted of only three lobes (Fig. 9B).
Expression of Spry-4 from E6.5 to E12.5 produced hypo-
plastic lungs with three instead of five lobes at E12.5 and
E13.5 (Fig. 4D and E). To determine the reversibility of the
effects of Spry-4, dams were treated with doxycycline from
E6.5, removed from doxycycline on E12.5 or E13.5, and
lung morphology was assessed at E18.5. When doxycycline
was provided to the dam from E6.5 to E12.5 and then
removed, lobulation was corrected, five lobes being present
at E18.5. Caudal and accessory lobes were fused, but sep-
arate main stem bronchi were observed. Peripheral lung
tissue was extensively restored, and epithelial cells ex-
pressed appropriate proximal (CCSP) and distal (SP-C) cell
markers after removal from doxycycline (Fig. 9C, and data
not shown). In contrast, termination of doxycycline 1 day
later (E13.5) resulted in hypoplastic lungs with three lobes
at E18.5. Spry-4 expression until E13.5 resulted in loss of
the ability to reinitiate branching of both the right caudal
Fig. 8. FGF-10, FGF-18, Spry-2, and Spry-4 mRNAs at E13.5. Lungs from
control (A, C, E, G) and transgenic SP-C-rtTA/(tetO)7Spry-4 (B, D, F, H)
embryos at E13.5 (doxycycline from E6.5–E13.5) were analyzed for
FGF-10 (A, B), FGF-18 (C, D), Spry-2 (E, F), and Spry-4 (G, H) mRNA
by in situ hybridization. No specific staining was found in sense-probe
controls (bar, 50 m).
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and the accessory lobes (Fig. 9D). Thus, prior to E12.5,
Spry-4 reversibly inhibited lung lobulation. Inhibitory ef-
fects of Spry-4 on branching morphogenesis were not re-
versible after E13.5. Expression of Spry-4 from E12.5 to
E18.5 did not influence lobulation (Fig. 9E).
Effects of Spry-4 on lung growth and survival in the
perinatal period
To investigate the temporal effects of Sprouty4 on lung
growth, pregnant dams were given doxycycline at various
time points before or after E12.5. Fetal lung weights were
assessed at E18.5 and expressed as percent of total body
weight. After expression of Spry-4 from E12.5 or E13.5 to
E18.5, lung/body weight ratios (1.1  0.04%) were signif-
icantly more reduced than in mice treated from E6.5 to
E12.5 (1.5  0.14%; P  0.03) or from E14.5 and E16.5 to
E18.5 (1.4  0.11%; P  0.02) by ANOVA. Thus, E12.5–
E13.5 is a critical time period during which both branching
and growth of the lung are most sensitive to Spry-4.
Treatment of double transgenic mice with doxycycline
from E14.5 or E16.5 to E18.5 significantly reduced lung
weight from 2.6  0.05% to 1.4  0.11% (P  0.0001) by
ANOVA. Thus, Spry-4 inhibits lung growth between E16.5
and E18.5. Double transgenic mice treated with doxycycline
between E14.5 and E18.5 or E16.5 to E18.5 had no defects
in lobulation (data not shown) but never survived perinatal
due to respiratory failure. Electron microscopy and expres-
sion studies for SP-C and SP-B showed no obvious devel-
opmental defects in these lungs. Thus, the perinatal cause of
death in these mice remains unclear.
Expression of Spry-4 from E18.5 and throughout post-
natal alveolarization did not interfere with perinatal survival
and caused noninflammatory emphysema in mice detected
at PN 21 days of age (Fig. 10). Expression of Spry-4 for 3
months in adult mice had no effect on changes in lung
architecture (data not shown). Thus, Spry-4 expression in
the perinatal period did not cause respiratory failure but
modestly impaired alveolarization.
Vascular development
Vascular components of the lung were identified by
immunohistochemistry for platelet endothelial cell adhesion
molecule (PECAM) during the saccular stage of lung de-
velopment (E17.5–E18.5) (Fig. 11). Large pulmonary ves-
sels were apparent in the lungs of all mice. Peripheral
pulmonary vessels were markedly reduced in the hypoplas-
tic lungs seen after continuous treatment of the dam with
doxycycline (Fig. 11B). The distribution and intensity of
PECAM staining in the hypoplastic tissue was not altered
by expression of Spry-4 from E6.5 to E13.5 or from E12.5
to E18.5 (Fig. 11C and D).
Discussion
Effects of Spry-4, an intracellular inhibitor of FGF-sig-
naling, on lung growth and morphogenesis were dependent
on the stage of development. Inhibitory effects of Spry-4 on
branching were observed before E13.5, and were reversible
until, but not after, this age. Maintenance of cell differen-
tiation and proliferation in residual tissues support the con-
cept that the Spry-4 inhibits commitment or expansion of
critical populations of progenitor cells in the embryonic
period of development. Effects of Spry-4 between E16.5
and E18.5 in gestation revealed inhibitory effects on lung
growth and postnatal survival. Expression of Spry-4 in the
perinatal period caused focal emphysema. Taken together,
these findings support the concept that FGF signaling is
required for early branching morphogenesis and for survival
and proliferation of progenitor cells that contribute to the
peripheral lung later in development.
Both Spry-2 and Spry-4 are expressed in epithelial cells
and surrounding mesenchyme of the fetal lung, respectively.
Neither Spry-2 nor Spry-4 encodes a leader sequence, and
both are thought to act in a cell-autonomous manner to
inhibit tyrosine kinase signaling following FGF activation.
While Spry is thought to act primarily as an inhibitor of the
FGF pathways, in some tissues (e.g., the retina), EGF sig-
naling was also inhibited by DSpry (Kramer et al., 1999;
Egan et al., 2002). The marked inhibitory effects of Spry-4
on lung morphogenesis are similar to those previously ob-
served after expression of a dominant-negative FGF recep-
tor or Spry-2 in epithelial cells of the developing lung
(Peters et al., 1994; Mailleux et al., 2001). Together with
previous studies that demonstrated the arrest of lung forma-
tion in FGF-10 and FGF-R2IIIb transgenic mice, the present
observations are consistent with the inhibitory effects of
Spry-4 on FGF signaling. In contrast, inhibition of EGFR
signaling as seen in waved-2 mice (Luetteke et al., 1994) or
mice deficient of a functional EGF receptor (Miettinen et
al., 1997; Sibilia and Wagner, 1995) did not perturb lung
morphogenesis, postnatal survival, or lung architecture.
Thus, the present findings are consistent with inhibitory
effects of Spry-4 primarily on FGF-, rather than EGF-
dependent pathways.
Loss of lobar bronchi and abnormalities in lobulation,
seen after Spry-4 expression, are consistent with the tem-
poral and spatial expression of the transgene. The SP-C
promoter is active early in lung morphogenesis, being
readily detected by E10 (Wert et al., 1993). As demon-
strated in Perl et al. (2002b), doxycycline-induced hSP-C
driven transgene expression is highly restricted to the pro-
genitor cells of the peripheral lung epithelium before E8.5.
After E10, the hSP-C promoter is active in most of the
epithelial cells in the periphery of the fetal mouse lung and
in epithelial cells of the conducting airways. The trachea
was unaltered in the SP-C-rtTA/(tetO)7Spry-4 mice, in spite
of marked inhibition of peripheral lung growth. In contrast,
distal trachea and bronchi were absent in FGF-10 gene-
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targeted mice. Although SP-C transgenes are expressed as
early as E10 and persist at high levels thereafter, Spry had
no observable effect on formation of the trachea. This ob-
servation may be related to the spatial and temporal restric-
tion of rtTA expression under the control of the SP-C or to
precise stochiometric requirements for Spry-4 to exert its
inhibitory effects. Alternatively, growth of the more proxi-
mal elements of the trachea may not be sensitive to Spry-4.
Spry-4 inhibited growth of the lung periphery but did not
alter cytodifferentiation of respiratory epithelial cells. The
proximal–distal patterns of epithelial cell differentiation
were maintained in the residual lung tissue in the Spry-4
transgenic mice. Epithelial cell markers, including CCSP,
were expressed in nonciliated epithelial cells at appropriate
times and sites. In spite of expression of Spry-4 in periph-
eral respiratory epithelial cells, these cells expressed appro-
priate differentiation-dependent markers and developed ul-
trastructural features consistent with normal lung
differentiation. Vascular and other mesenchymal compo-
nents of the lung were lost in proportion to the diminished
epithelial compartment. These findings are consistent with
the maintenance of a careful balance between mesenchymal
and epithelial components of the lung during morphogene-
sis, a process likely to be determined by the appropriate
production of signaling molecules between the mesenchyme
and epithelium.
The specificity, timing, and substantial reversibility of
lung hypoplasia seen after withdrawal of doxycycline, and
with it the cessation of Spry-4 expression, support the con-
cept that Spry-4-sensitive pathways are not required
throughout lung morphogenesis for proliferation of lung
epithelial cell progenitors. Spry-4 expression did not change
the percentage of mitotic cells. Expression of Spry-4 in lung
explants inhibited the branching of existing lung tubes but
did not inhibit their elongation. Thus, the loss of peripheral
lung epithelium in development is not readily explained by
an ongoing inhibition of cell proliferation. Rather, effects of
Spry may be mediated by a temporally restricted require-
ment for FGF signaling that mediates commitment and/or
expansion of subsets of peripheral lung progenitor cells
during the embryonic phase of lung morphogenesis at or
before E12.5. This finding is consistent with the findings
that FGF10 is expressed at highly restricted sites at the tips
of respiratory tubes (Weaver et al., 2000). Loss of this pool
of progenitors presumably is related to the loss of signaling
from FGF-10 via the FGFR2IIIb receptor, which reduced
branching, whereas the mitotic index in the remaining cell
pool was maintained. Between E14.5 and E16.5, lung
growth appears to be less sensitive to Spry-4 expression.
The concept that FGF signaling is required for survival and
proliferation of a subset of progenitor cells is supported by
findings in which progenitor cells of the peripheral lung
were identified at the tips of lung tubules and at sites of
lateral branching at E11.5. Expansion of these progenitor
cells did not occur until E12.5, and these cells contribute to
the majority of epithelial cells from which the peripheral
lung is formed (Perl et al., 2002b). Effects of Spry-4 were
less severe before E12.5 and after E14.5. Thus, E12.5–
E14.5 appears to be a critical time period during which
progenitor cells require FGF signals for lobulation and lung
growth.
Fig. 9. Reversibility of the effects of Spry-4 on lung lobulation. Lungs from
E18.5 double transgenic SP-C-rtTA/(tetO)7Spry-4 mice are shown. All
lobes are indicated by numbers: 1, cranial; 2, medial; 3, caudal; 4, acces-
sory; 5, left lobe. Dams were untreated (A) or treated with doxycycline
from E0 to E18.5 (B), E6.5 to E12.5 (C), E6.5 to E13.5 (D), E12.5 to E18.5
(E), and E14.5 to E18.5 (F). (Bar, 2 mm).
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The effects of Spry-4 on growth and lobulation were
largely reversible until E13.5. Furthermore, Spry-4 had
lesser effects on lung structure when the mice were treated
with doxycycline after E13.5. Since peripheral lung growth
in the Spry-4-expressing mice was not restored unless doxy-
cycline was removed before E13.5, severe lung hypoplasia
caused by Spry may reflect a permanent loss of peripheral
lung progenitor cells whose commitment, maintenance, and
early expansion require FGF signaling during a critical time
period. The present findings are consistent with recent stud-
ies in which FGF signaling was inhibited by using a FGFR-
Hfc (Hokuto et al., 2003). In these studies, effects of FGFR-
Hfc on lung growth and lobulation were less reversible
when compared with mice expressing Spry-4. Spry-4 an-
Fig. 10. Emphysema after expression of Spry-4 from E18.5 to PN21. Histology of lungs from double transgenic SP-C-rtTA/(tetO)7Spry-4 9 (B, D, F) mice
and control littermates (A, C, E) are shown after doxycycline treatment from E18.5 to PN21. Lungs were stained with hematoxilyn and eosin (A, B), orcein
(C, D), and trichrome (E, F). Focal emphysema was detected without evidence of inflammation or fibrosis. Elastin staining (C, D) was unchanged. (A, B:
bar, 100 m; C–F: bar, 50 m).
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tagonizes FGFR signaling in the epithelium, whereas
FGFR-Hfc is likely to antagonize FGFR signaling in both
epithelium and mesenchyme. From the differences in these
two models, we hypothesize that FGF signaling may also
occur from the epithelium to the mesenchyme, perhaps
resulting in the survival and proliferation of epithelial pro-
genitor cells.
The finding that expression of Spry-4 enhanced FGF-10
and FGF-18 expression in the mesenchyme may reflect a
compensatory effect for the lack of FGF signaling from the
mesenchyme to the epithelium.
Inhibition of FGFR signaling by Spry-4 expression from
E17.5 to PN28 caused focal and mild emphysema at PN28,
demonstrating that progenitor cells involved in alveolarization
are sensitive to Spy in the early postnatal period. The role of
FGF signaling in postnatal alveolarization is supported by
findings in FGFR3/FGFR4 double knockout mice (Weinstein
et al., 1998). Inhibition of FGFR signaling by expression of a
soluble FGFR (FGFR-Hfc) from E14.5 to E18.5 caused post-
natal emphysema. In contrast, expression of FGFR-Hfc during
postnatal alveolarization had no effect on lung morphology
(Hokuto et al., 2003). Taken together, these data support the
concept that progenitor cells, which form the secondary alve-
olar septae, are dependent on FGF/FGFR signaling during the
canalicular and saccular stage but not during alveoloarization
per se. Spry-4 expression during the canalicular and saccular
stage results in perinatal lethality.
The timing of the signaling events mediating lung hyp-
oplasia in our experiments is dependent on the time of onset
and reversibility of the doxycycline-dependent transgene. In
previous studies, SP-C-rtTA-dependent expression of lucif-
erase in the adult lung was detected 6 h after treatment of
double transgenic mice or in the fetal lung within 12 h after
administration of doxycycline to the dam. Levels of trans-
gene expression decreased rapidly within 24 h after removal
of doxycycline in adult mice (Perl et al., 2002a; Tichelaar et
al., 2000). Likewise, the concentration of doxycycline re-
quired to induce levels of Spry-4 sufficient to inhibit FGF
signaling also complicates an estimation of the precise tim-
ing in the present experiments. Nevertheless, our studies
suggest that Spry-4-dependent pathways are most critical
for survival and expansion of peripheral progenitor cells
before the end of the pseudoglandular period of lung devel-
opment (E13–E14).
Fig. 11. PECAM staining of the pulmonary vasculature. PECAM was assessed in lungs from E17.5-old wild type (A) and double transgenic SP-C-rtTA/
(tetO)7Spry-4 at E17.5 (B) and at E18.5 (C, D) mice. The dam was treated with doxycycline from E6.5 to E17.5 (A, B), E6.5 to E12.5 (C), or E12.5 to E18.5
(D). While large pulmonary arteries were present in lungs from mice expressing Spry-4, capillaries were deficient in the lung parenchyma consistent with
the loss of alveolar structures (B). Histology and immunohistochemical staining for PECAM revealed no obvious malformations at E18.5 when Spry-4 was
expressed from E6.5 to E12.5 or E12.5 to E18.5 (C, D) (Bar, 50 m). Note: Red blood cells in (B) and (D) are due to a preparation artifact and not due to
hemorrhages.
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The studies presented support a model of temporal-
restricted FGF signaling, which is required for commit-
ment and survival of a restricted subset of progenitor
cells that forms the majority of the peripheral lung in the
fetus. A model in which continuous activity of FGF
signaling is required for proliferation and differentiation
throughout pulmonary morphogenesis is not supported by
our findings. The observed reversibility of the effects of
Spry-4 on branching suggests that peripheral lung pro-
genitor cells are capable of establishing cell lineages in
the late pseudoglandular period, after the formation of
lobar bronchi, but before proliferation of the peripheral
lung that occurs from E13.5 and thereafter. Later in fetal
development (E13.5–E14.5), signaling via Spry-4-sensi-
tive pathways exerts a lesser effect on lung growth and
morphogenesis. Postnatal lung morphogenesis was not
greatly affected by Spry-4. While recovery from lung
hypoplasia following expression of Spry-4 was tempo-
rally restricted, the ability of the lung to resume branch-
ing morphogenesis was remarkable. Such observations
may be of critical importance in understanding clinical
syndromes causing lung hypoplasia and emphysema. In
human infants, loss of amniotic fluid and chest compres-
sion by other organs as in diaphragmatic hernia or oli-
gohydramnios caused by renal abnormalities often cause
lung hypoplasia, resulting in respiratory failure at birth.
Effects of oligohydramnios are highly temporally re-
stricted, being most marked in midgestation (weeks 16 –
20) during the canalicular phase of human lung develop-
ment. Lethal lung hypoplasia is generally not seen after
loss of amniotic fluid later in gestation (after 24 weeks).
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